Results 191 to 200 of about 96,770 (285)

The impact of dose and discontinuation timing of preoperative ACE inhibitors on survival outcomes in cardiac surgery: A MIMIC-IV database analysis. [PDF]

PLoS One
Zou X, Chen S, Hu L, Sha L, Zhou J, Qiu H, Wu X.   +6 more
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

ACE Inhibitors and ARBs in Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials on Albuminuria Reduction, eGFR Decline, and Safety. [PDF]

Cureus
Avula A, Johal LK, Ali F, Amir S, Yadav S, Murtuza M, Zia U, Janjua FF, Raza A, Lal K, Abid M, Khan R.   +11 more
europepmc   +1 more source

ACE Inhibitor [PDF]

, 2020
openaire   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Higher Risk of Kidney Failure Associated With Angiotensin Receptor Blockers vs ACE Inhibitors in Patients With Heart Failure. [PDF]

Am J Med
Moore HJ, Wu WC, Heidenreich PA, Rossignol P, Patel SS, Lu F, Lam PH, Ahmed AA, Faselis C, Butler J, Palant CE, Pitt B, Weir MR, Deedwania P, Atkins D, Raman VK, Rangaswami J, Vargas JD, Zhang S, Morgan CJ, Sheriff HM, Zeng-Treitler Q, Fonarow GC, Ahmed A.   +23 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Investigating potent cardioprotective compounds as ACE inhibitors in Saraca asoca. [PDF]

Toxicol Rep
Prasad S, Younis K, Yousuf O.
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials. [PDF]

JACC Adv
Evbayekha E, Idowu AB, LaRue S.
europepmc   +1 more source